DEF 14A: Johnson & Johnson's 2024 Proxy Statement: Board Elections, Executive Pay, and Shareholder Proposals

Johnson & Johnson's 2024 proxy statement outlines key governance matters, including director elections, executive compensation, and shareholder proposals.

Summary

• The document is Johnson & Johnson's proxy statement for its 2024 Annual Meeting of Shareholders.
• The meeting will be held virtually on April 25, 2024, and shareholders of record as of February 27, 2024, are eligible to vote.
• The proxy statement includes information on the election of 13 director nominees, an advisory vote on executive compensation, ratification of the appointment of PricewaterhouseCoopers LLP as the independent auditor, and two shareholder proposals.
• The Board recommends voting FOR the election of all director nominees and the ratification of the auditor, and AGAINST the shareholder proposals.
• The document details the company's corporate governance practices, board structure, executive compensation programs, and risk oversight.
• It also discusses the company's commitment to its Credo, environmental, social, and governance (ESG) initiatives, and shareholder engagement.
• The proxy statement includes information on director and executive compensation, stock ownership, and related person transactions.
• The document also provides information on how to attend the annual meeting, vote shares, and contact the Board of Directors.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting strong financial performance and strategic achievements. However, it also acknowledges challenges related to litigation and the separation of Kenvue, resulting in a moderate sentiment score.

Positives

• The Board has a proven record of strategic and consistent refreshment, seeking new Directors with appropriate skills, qualifications and backgrounds.
• The Board is committed to diversity, reflecting differences in skills, regional and industry experience, background, race, ethnicity, gender and other unique characteristics.
• The company has comprehensive compensation recoupment policies designed to ensure that management is held accountable in the event of specified misconduct or financial restatements.
• The company has a policy prohibiting directors and executive officers from pledging, hedging or short selling Company stock.
• The company has a comprehensive Code of Business Conduct designed to provide directors, senior executives and employees with guidance on our Company’s compliance policies.
• The company has an Enterprise Risk Management (ERM) Framework that provides a coordinated, integrated and aggregated process for managing risks across the Enterprise.
• The company has an anonymous telephone and online reporting program known as Our Credo Integrity Line that allows employees, business partners, customers, third-party agencies, suppliers and other parties to report potential violations of Company policies, guidelines or applicable law.
• The company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company.
• The company has a formal information security training program for all employees that includes training on matters such as phishing and email security best practices.
• The company has a strong commitment to expanding patient access to its products.
• The company has a strong commitment to workplace diversity and to a culture of equity and inclusion.
• The company has a strong commitment to supporting the development of sound health policies.
• The company has a strong commitment to protecting its information assets and business integrity.

Negatives

• The company agreed to contribute up to the present value of $8.9 billion, payable over 25 years, to resolve all current and future talc claims against the Company and its affiliates in North America.
• The company disclosed an accounting charge of $6.9 billion in the first quarter of 2023 and accrued an additional $0.2 billion in the second quarter related to talc claims.
• The company has made no admission of wrongdoing, nor has the Company changed its longstanding position that its talcum powder products are safe.
• The company has prevailed in the majority of cases tried and continues to stress that the talc claims are unfounded and lack scientific merit.
• The company's 2021-2023 TSR compound annual growth rate fell below target.

Risks

• The proxy statement contains forward-looking statements, and actual results could vary materially from expectations due to various risks and uncertainties.
• These risks and uncertainties include economic factors, competition, challenges in research and development, patent challenges, manufacturing difficulties, product efficacy or safety concerns, litigation, changes in laws and regulations, and financial instability of international economies.
• The company's ability to realize the anticipated benefits from the separation of Kenvue Inc. is also a risk factor.
• Kenvue Inc.'s ability to succeed as a standalone publicly traded company is also a risk factor.

Future Outlook

The Company is excited for Johnson & Johnsons future, and the Board is unwavering in its support of the Companys commitment to tackling the worlds toughest health challenges.

Management Comments

• Johnson & Johnson has emerged as a two-segment company with a new brand identity focused exclusively on healthcare and uniquely positioned to lead the next wave of innovation.
• The Board championed the Companys investment in data science and digital capabilities as foundational to its innovation goals.
• We are extremely excited for Johnson & Johnsons future, and the Board is unwavering in its support of the Companys commitment to tackling the worlds toughest health challenges.

Industry Context

The announcement relates to broader industry trends of corporate governance, executive compensation, and shareholder engagement. The company's focus on ESG and transparency aligns with increasing investor expectations for corporate responsibility.

Comparison to Industry Standards

• The company compares its executive compensation levels and practices to those of an executive peer group consisting of companies that are similar in size and scope, have executive positions similar to ours and compete with us for executive talent.
• The company also compares overall Company performance to the weighted performance of the competitor composite peer group companies.
• The company's executive peer group includes 3M Company, Abbott Laboratories, Abbvie Inc., Amgen Inc., AT&T Inc., The Boeing Company, Bristol Myers Squibb Company, Cisco Systems, Inc., Eli Lilly and Company, General Electric Company, Gilead Sciences, Inc., Intel Corporation, Intl Business Machines Corp., Medtronic plc, Merck & Co., Inc., Microsoft Corporation, Pfizer Inc., The Procter & Gamble Company, Raytheon Technologies Corporation.
• The company's competitor composite peer group includes companies in the Innovative Medicine, MedTech, and Consumer Health sectors.

Legal Proceedings

• Johnson & Johnson agreed to contribute up to the present value of $8.9 billion, payable over 25 years, to resolve all current and future talc claims against the Company and its affiliates in North America.

Related Party Transactions

• A sister of Mr. Wolk, Executive Vice President, Chief Financial Officer, is a Mobility Operations Leader at Johnson & Johnson Services, Inc., a wholly-owned subsidiary of the Company, and earned $209,351 in total compensation in 2023.
• Ms. Kathryn Wengel is Executive Vice President, Chief Technical Operations & Risk Officer. Ms. Wengels brother-in-law is a partner at the law firm of Nelson Mullins Riley & Scarborough LLP (Nelson Mullins). The Company has engaged Nelson Mullins for more than twenty years. In 2023, the Company paid approximately $16 million to Nelson Mullins for legal services.

Stakeholder Impact

• The company's actions and decisions impact various stakeholders, including shareholders, employees, customers, patients, and communities.
• The company's commitment to its Credo guides its responsibilities to these stakeholders.
• The company's ESG initiatives aim to create financial value by building stakeholder trust, driving innovation, mitigating risk, fostering employee engagement, and promoting productivity.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on April 25, 2024.
• The company will continue to engage with shareholders on corporate governance and executive compensation matters.
• The company will release a report on the racial justice audit in 2024.

Key Dates

Keywords

proxy statement, corporate governance, executive compensation, board of directors, shareholder proposals, annual meeting, Johnson & Johnson, PricewaterhouseCoopers, audit, directors, compensation, shareholders, Kenvue, ESG, risk management